elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1A
Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1A
Growth factor use in medication-induced hematologic toxicity.
P2860
Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33417812-7CC89E3B-4F76-48A4-B4E8-CE95C9E03E1A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ce6626bf840747a880ee442a2f7317c6f7cafe8d
P2860
XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.